Om

Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid pain medicines. Its current programs are built around NaV1.8 inhibitors, a class of compounds designed to interrupt pain signaling at its source while avoiding the addiction risks associated with opioid therapies. The company’s pipeline includes candidates for acute pain, chronic musculoskeletal pain, and broader acute and chronic pain applications, with oral and intravenous formulations in development. Latigo Biotherapeutics serves the pain-management market by advancing targeted therapies intended for use in settings such as postoperative care, musculoskeletal disorders, and other medically significant pain conditions. Headquartered in Thousand Oaks, California, the company operates within the biotechnology sector and is centered on creating differentiated treatments that address unmet needs in non-opioid pain control.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I LATIGO BIOTHERAPEUTICS MED ENDAVU: Køb Latigo Biotherapeutics ($LTGO) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Latigo Biotherapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.